PubMed Health⌕ Search

Biomedical subjects

E Dziuk

Publications and source records attributed to E Dziuk.

At least 37 records · Page 2Linked to original sources
PubMed1978

[Accidental contamination with cesium-137].

The paper describes an accidental 137Cs internal and external contamination of a woman 28 years old by handling of two unsealed 137Cs sources of 2.5 Ci total activity. The only abnormality found by laboratory tests was leukopenia. The chromosomes of blood lymphocytes were also investigated. 137Cs content in urine between the 8th and 40th day after accident ranged from 34, 53 to 12.01 nCi/day. The mean feces: urine ratio was 0.25 +/- 0.06. The increase of 137Cs excretion in urine, after administration of diurectic "Lasix" and potassium was not observed. Mean biological half-life calculated from regression curve was 64 days. Body content found by whole body counting, performed on the 8th and 15th day after accident, was 6.5 muCi and 5.1 muCi respectively. The initial 137Cs body burden of 6.9 muCi was calculated for the value 5.1 muCi. The corresponding total radiation dose was 0.26 rads and quarterly dose was 0.16 rads.

Accidents↗
PubMed1976

Patterns of changes in peripheral blood composition in the course of combination chemotherapy of cancer.

During MOPP (mechloretamine, vincristine, procarbasine and prednisone) chemotherapy in Hodgkin's disease a pattern of haematological injury develops gradually, and the period of maximal disturbances in peripheral blood parameters includes the last two or three months (the last 2 or 3 courses) of treatment with insufficient rebound between the courses. On the contrary, in the case of "synchronization" chemotherapy (vincristine and cyclophosphamide) in lung cancer a pattern of haematological injury develops rapidly, and the period of maximal disturbances in peripheral blood parameters takes only a few days, 7-12 days after each course, with sufficient or enhanced rebound between the courses. These differences are probably due to different scheduling of drugs in these methods of therapy.

Adult↗
PubMed1976

Combination of ametopterine (MTX) and cyclophosphamide (CPM) based on the principle of partial synchronization of cell proliferation in lung cancer. Phase II study.

Twenty-three patients with histologically proven bronchogenic carcinoma of the lung were treated with regimen consisting of 3 intravenous doses of 0.4 mg/kg of MTX and intravenous infusion of 30-50 mg/kg body weight of CPM. Interval between 1st and 2nd dose of MTX, which served as synchronizing agent in phase G1/S, was 12 hrs, and interval between 2nd and 3rd dose -- 6 hrs. Infusion of CPM, which was considered to be a preferably S-phase killer was started simultaneously with administration of 3rd dose of MTX. Such courses were repeated every 21-30 days. Objective responses were noted in 10 of 19 adequately treated patients. MTX-CPM favourably influenced survival of the responders. The therapy was, however associated with a number of adverse reactions, from which neutropenia and complicating bacterial infections were particularly dangerous.

Adult↗